TATAA Biocenter Expands Offerings using Roche´s RealTime ready Custom qPCR Assays and Panels

PENZBERG, Germany, February 22, 2012 /PRNewswire/ --

TATAA Biocenter, Europe´s leading provider of genomic services using quantitative real-time polymerase PCR (qPCR), is expanding its offerings to high-throughput gene expression profiling using Roche´s RealTime ready Custom qPCR Assays and Panels. TATAA Biocenter's laboratories provide contract research for a full range of real-time qPCR services, including primer and probe design, validation, data analysis, and kit and instrument evaluation to pharmaceutical and biotech companies. The company offers a seamless workflow, with all the instrumentation necessary for performing high quality experiments and for optimal sample handling, meeting the specific requirements for compliance with ISO17025 standard. TATAA laboratories are also available for academic researchers.

"The number of genes researchers characterize in a given sample is steadily increasing. In response to this demand, we now offer high-throughput profiling services in a complete workflow from nucleic acid extraction, gene profiling, and data mining," reported Dr. Mikael Kubista, founder and CEO of TATAA Biocenter. "After extensive testing and validation of the various offerings on the market, we selected the Roche RealTime ready platform for its excellent performance combined with a workflow with exceedingly user-friendly wizard-based data mining with GenEx from MultiD Analysis".  

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: http://www.roche.com.

About TATAA Biocenter

TATAA Biocenter is one of the leading research and service providers and organizers of hands-on training courses in qPCR in Europe. TATAA offers full range of real-time qPCR services including high throughput qPCR analysis, primer and probe design, assay validation, data analysis, testing and benchmarking of kits and instruments, and contract services to pharmaceutical and biotech companies. TATAA also organizes the annual qPCR symposium (http://www.qpcrsymposium.eu). Founded in 2001, TATAA has permanent facility in Gothenburg, Sweden, Sunnyvale, California, and Prague, Czech Republic.

For life science research only. Not for use in diagnostic procedures.

LIGHTCYCLER and REALTIME READY are trademarks of Roche.

Exiqon and ProbeLibrary are registered trademarks of Exiqon A/S, Vedbaek, Denmark.

All other product names and trademarks are the property of their respective owners.

For further information please contact:
Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49-8856-604830
Email: burkhard.ziebolz@roche.com